Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
Real-time Estimate
07:06:01 2026-04-30 am EDT
5-day change
1st Jan Change
115.28 CHF
+1.71%
-1.12%
+4.91%
Published on 04/30/2026
at 07:00 am EDT
Dow Jones
(MORE TO FOLLOW) Dow Jones Newswires
April 30, 2026 07:00 ET (11:00 GMT)
© Dow Jones –
2026
DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.
PeriodDayWeek
Novartis AG is one of the world’s leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows:
– oncology (30.9%);
– immunology (18.9%);
– cardiovascular, renal and metabolic diseases (16.4%);
– neuroscience (11%).
The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products.
At the end of 2025, Novartis AG had over 31 production sites worldwide.
Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Sell
Buy
Last Close Price
143.45USD
Average target price
153.80USD
Spread / Average Target
+7.21%
Quarterly revenue – Rate of surprise
OUR EXPERTS ARE HERE FOR YOU
Monday – Friday 9am-12pm / 2pm-6pm GMT + 1
Legal information
|
Cookie settings
|
MarketScreener Blog
|
About us
|
Copyright © 2026 Surperformance SAS. All rights reserved.
Stock quotes are provided by Factset, Morningstar and S&P Capital IQ
Select your edition
All financial news and data tailored to specific country editions
